Bata India Ltd. (BIL)



Similar documents
Flexituff International Ltd. (FIL)

PI Industries. 2QFY16 Result Review HOLD. Custom synthesis restricted 2Q revenue growth ; maintain HOLD. Sector: AGRI

Salzer Electronics. 2QFY16 Result Review BUY. Steady performance continued; maintain BUY. Sector: Electric Equipment

Strong operational performance

HCC BUY. Infrastructure January 29, 2016

Gujarat State Petronet Ltd. INR 135

SUPREME INDUSTRIES LTD Plastic Products HOLD RETAIL EQUITY RESEARCH

Mangalam Cement Weak volumes marred performance

GAIL (India) Ltd. INR 346

Accumulate. Exide Industries Ltd(EIL) Automobile Ancillaries RETAIL EQUITY RESEARCH

Minda Industries Ltd. INR 886

Coal India Ltd. Subdued e-auction realization impacted profitability BUY. Nov. 17, 2015

Techno Electric & Engineering Limited

Simplex Infrastructures

Tree House Education & Accessories

Shriram Transport Finance Subsidiaries witness sharp increase in NPA

The Ramco Cements. Source: Company Data; PL Research

Maruti Suzuki. Source: Company Data; PL Research

Results impacted by subdued demand

Navin Fluorine International

GlaxoSmithKline Consumer Healthcare

Britannia Industries

Emkay. Revenues traction improves; Retain BUY HSIL. Healthy revenue performance; miss on margins

UltraTech Cement Ltd.

Polaris BUY. Virtusa acquires majority in Polaris. Institutional Equity Research. November 05, Target Price Rs220. IT India.

BUY. Muted Q3; Brands & Retail story to unfold ARVIND. Target Price: Rs 344. Segmental highlights

Axis Bank. Strong core performance. Source: Company Data; PL Research

Higher other income drive the quarter

BUY. KELLTON TECH SOLUTIONS LTD Result Update (CONSOLIDATED): Q1 FY16. CMP Target Price JANUARY 9 th 2015 SYNOPSIS ISIN: INE164B01022

BUY GUJARAT STATE PETRONET. Operationally in line; other income surprises. Target Price: Rs 160. Valuations comfortable. Visible triggers ahead

PEER GROUPS CMP MARKET CAP EPS P/E (X) P/BV(X) DIVIDEND Company Name (Rs.) Rs. in mn. (Rs.) Ratio Ratio (%)

Company Overview. Financial Performance

Sundaram Finance. Target price (INR) 452 Momentum in loans sustains, upgrade to Hold

HOLD. The case of missing sales growth ZYDUS WELLNESS. Target Price: Rs 780. Q3highlights

Kotak Mahindra Bank Rs 685

HOLD. Q4 earnings beat but order backlog flat ABB. Target Price: Rs 1,213. Key drivers

RamKrishna Forgings Ltd.

BUY RSWM LTD SYNOPSIS. CMP Target Price SEPTEMBER 1 st Result Update(PARENT BASIS): Q1 FY16

Khambatta Securities Ltd.

BUY. ECLERX SERVICES LIMITED (CONSOLIDATED) Result Update: Q1 FY16. CMP Target Price SEPTEMBER 2 nd, 2015 SYNOPSIS ISIN: INE738I01010

HOLD HEXAWARE TECHNOLOGIES. Q4 lackluster; CY16 holds promise. Target Price: Rs 252. Q4earnings concall highlights

Mphasis. FY17 could be a year of revenue growth. Source: Company Data; PL Research

Bharat Electronics. Strong margins, improved inflows! Source: Company Data; PL Research

Greenply Industries Ltd

HOLD ASTRAL POLYTECHNIK. Q3 muted; recovery ahead. Target Price: Rs 377. Key highlights. Key drivers

Va Tech Wabag. Source: Company Data; PL Research

Butterfly Gandhimathi (GANAP) 188

BUY. Key Risks. Technology - Technology Services - Information Services. Nov 19, CRISIL Ltd. Recommendation (Rs.)

CMP: JUNE 2016 SWARAJ ENGINES LTD

Just Dial Ltd Bloomberg Code: JUST IN

Pidilite Industries. Source: Company Data; PL Research

India Equity Research Telecommunications September 2, 2015 Management Meet Update

Granules India Ltd. INR 113

JSW Energy Ltd. Interest expenses dragged the bottom-line BUY. Jan. 25, 2016

How To Value Hpl In India

PEER GROUPS CMP MARKET CAP EPS P/E (X) P/BV(X) DIVIDEND Company Name (Rs.) Rs. in mn. (Rs.) Ratio Ratio (%)

YES Bank HOLD. Not out of the woods yet; Asset quality remains a key monitorable. Institutional Equity Research. January 30, Target Price Rs788

Outlook and valuation

East India Hotels (EIH) Ltd Growing Strategically

HCL Technologies BUY. Performance Highlights CMP. `857 Target Price `1,132. 1QFY2016 Result Update IT. 3-year price chart

Techno Electric & Engineering Co Ltd

BUY. Lower realization impacts earnings CAIRN INDIA. Target Price: Rs 155. Analyst call highlights

Jubilant Life Sciences

East India Hotels (EIH) 114

Orchid Chemicals NEUTRAL. Performance Highlights. Target Price - 1QFY2011 Result Update Pharmaceutical. Investment Period -

BUY. JYOTHY LABORATORIES LTD Result Update (CONSOLIDATED BASIS): Q2 FY16. CMP Target Price DECEMBER 29 th 2015.

BDI BioEnergy Intern Neutral. Activity level in Q3 might not support FY estimates

Wipro BUY. Performance Highlights CMP. `573 Target Price `719. 2QFY2016 Result Update IT. Investment Period 12 Months. 3-year price chart

Margins to remain in mid 15% range for FY 16E, increase in FY 17E on operating leverage

Private drilling fluid technology service leader

RAJESH EXPORTS LIMITED GLOBAL PRESENCE IN GOLD AND GOLD PRODUCTS. Earnings Presentation Q2 FY16

Cipla Ltd. Rs India Equity Institutional Research Pharma. One off revenues from Nexium supply drives earnings HOLD. Target Price (Rs): 765

Quant Picks United Breweries

Rating Change 1 February 2016

MAITHAN ALLOYS LTD Result Update (PARENT BASIS): Q4 FY16

Exhibit 1: Financial summary of First Tractor in 1H12-1H14 1H12 2H12 1H13 2H13 1H14 (% YoY)

Bata India BUY. Favourable base shores up Q3, BUY. Results Review INDIA TP: INR % BATA IN

Bharat Earth Movers (BEML)

BUY Target: 215p. Strategic impact: cross-selling. Financial impact: good value

Bharti Infratel (BHAINF) 370

Larsen & Toubro. Source: Company Data; PL Research

How To Understand And Value Gsk Pharma

Satisfactory Top-Line; Disappointing Bottom-Line

Year-end Dec 2013A 2014E 2015E 2016E Key data. # Priced at market close, 29/09/14

HINDUSTAN COMPOSITES LTD Result Update (PARENT BASIS): Q4 FY16

Graphite Electrodes. Imposition of antidumping duty augurs well. Sector Update. ICICI Securities Ltd Retail Equity Research.

HEG Ltd (HEG) 160. Performs well. Result Update. ICICI Securities Ltd Retail Equity Research. November 10, 2015

In line performance. Results update 4Q2015. Banks UAE 28 January 2016 DUBAI ISLAMIC BANK

PEER GROUPS CMP MARKET CAP EPS P/E (X) P/BV(X) DIVIDEND Company Name (Rs.) Rs. in mn. (Rs.) Ratio Ratio (%)

Mahindra CIE Automotive Ltd.

East India Hotels (EIH) 109

DATRON AG. Investor day supports our positive view. Buy (Buy) EUR (12.50 EUR ) BANKHAUS LAMPE // 1 17/09/2015

Transcription:

Nov-14 Dec-14 Jan-15 Feb-15 Mar-15 Apr-15 May-15 Jun-15 Jul-15 Aug-15 Sep-15 Oct-15 Q2FY16 Result Review (Wholly owned subsidiary of Bank of Baroda) BUY Bata India Ltd. (BIL) Cloudy quarter sunshine ahead; maintain BUY Bata India Ltd. (BIL) reported 2QFY16 result with revenue growth of 5% YoY to Rs 5.7bn and EBITDA declined by ~23 YoY to Rs.491mn due to weak demand, supply chain issue, higher discounts & promotional costs. Reported PAT increased by ~39% YoY to Rs.541mn vs Rs.390mn mainly due to gain from exceptional items. Sluggish revenue growth: BIL s topline increased only by 5% YoY to Rs.5.7bn in 2QFY16 due to lower consumer sentiment, weak demand and supply chain issue. However, the company is currently widening its product portfolio; training its staff to improve the quality of shopping experience; putting efforts towards solving the implementation of SAP/ERP systems. With all these measures, the company is expected to recover and show a healthy growth in revenue going forward. We expect the company to maintain the growth rate at CAGR of ~11.6% over FY15-18E backed by volume growth, strengthening e-commerce business and enhanced versatility in its product portfolio. A ~308 bps declined in EBIDTA margin to 8.5% v/s 11.6% YoY: BIL s EBITDA margin declined by ~308 bps YoY to 8.5% as against 11.6% in 2QFY15. EBITDA for 2QFY16 stood at Rs.491mn v/s Rs.636mn in 2QFY16 a decline of ~23%/43% YoY/QoQ respectively mainly due to high rental costs, increase in other expenses & many promotional schemes to liquidate the inventory. Price Price Target Up/Down (%) Rs. 476 Rs. 571 Bloomberg Code BATA: IN Share Holding (%) BATA.NS Promoters 52.9 FII 11.88 DIIs 15.11 Stock Data Sector: Footwear 18 th Nov, 2015 20% Reuters Code As on 30th September 2015 Nifty 7,732 Sensex 25,483 52 week high/low 748/458 Maket Cap (Rs. bn) 61.2 Face Value Rs. 5 Price performance (%) 1M 3M 6M 1Y Absolute -9.9-19.2-10.4-27.2 Relative to Sensex -3.7-10.8-2.5-18.0 Reported PAT grew by ~39% YoY: BIL s reported PAT grew by ~39% YoY to Rs.541mn but adjusted profit (excluding exceptional items) declined by ~42% YoY to Rs.224mn in 2QFY16 as against Rs.390mn in 1QFY15. Exceptional items represent gain from sale of trademark (Sparx) of Rs.60.8cr and expenditure incurred (except the expenditure on perpetual license) amounting to Rs.29.1cr on setbacks in implementation of ERP system. Focusing on premiumisation: BIL is the largest footwear retailer in India with a high market share in the organized sector. The Company has strong pan-india presence with ~1,265 Shoe Stores located in over 500 cities. Of these there are 1,121 Bata, 102 Hush Puppies and 42 Footin Stores. In order to improve volume and profitability the company is focusing on rationalizing its stores; opening ~70-73 new exclusive outlets of premium brands like Hush Puppies, Naturalizer and Marie Claire in FY16. Strengthening online presence: BIL is strengthening its online presence by launching exclusive online portfolio, which will help in augmenting its online presence and also set up uniqueness amidst high competition. Relative Performance 120 110 100 90 80 70 60 50 Source:-Bloomberg Bata India BSE Sensex Valuation: Although the company had a slow growth due to teething problem in supply chain and lower consumer sentiments, we still believe that BIL would be back on track and poised for strong growth on account of premiumisation, expansions of product ranges, strengthening online presence and distribution network. At CMP of Rs.476, the stock is trading at around 37.4/32.4/25x of FY16/17/18e. We maintain BUY rating with target price of Rs.571 (upside 20%). Exhibit 1: Financial summary (Rs mn) Year end: March CY13 FY15(15M) FY16 FY17 FY18 Net sales 20,652 26,940 23,726 26,574 30,560 Growth (%) 12.1 30.4 7.9 12.0 15.0 Operating margin (%) 15.6 12.4 11.8 12.2 13.6 PAT 1,909 2,313 1,637 1,887 2,448 Adjusted PAT 2,010 1,997 1,637 1,887 2,448 EPS (Rs) 15.6 15.5 12.7 14.7 19.0 P/E(x) 30.4 30.6 37.4 32.4 25.0 ROE (%) 27.1 22.1 15.5 16.0 18.2 ROCE (%) 25.0 20.3 14.8 15.2 17.3 Akanksha Tripathi akanksha.tripathi@bobcaps.in +91 22 6138 9383

Exhibit 2: Q2FY16 Quarterly financials (Rs Mn) 2QFY16 3QFY15 YoY (%) 1QFY16 Net Sales 5,752 5,476 5.02 6,799-15.41 Other Related Income 2 3 6 Total Income 5,754 5,480 6,805 Total Expenses 5,263 4,844 5,941 (%) of net sales 91% 88% 87% (Increase)/ decrease in stock -960-740 -366 Raw material consumed 971 1,012 1,127 (%) of net sales 17% 18% 17% Staff cost 663 653 666 (%) of net sales 12% 12% 10% Manufacturing & Other Expenses 1,899 1,680 1,762 (%) of net sales 33% 31% 26% EBITDA 491 636-22.89 864-43.25 EBITDA Margin 8.5 11.6 12.7 Depreciation 192 155 159 EBIT 299 481-37.96 705-57.68 Interest 4 3 5 Other Income 82 106 44 PBT 376 584 744-49.40 Less: Taxation 153 194 251 Tax / PBT 41% 33% 34% Recurring PAT 224 390-42.68 493-54.64 Exceptional items (income)/expense -318 0-430 Less: Minority Interest 0 0 0 Reported PAT 541 390 38.72 922-41.34 NPM 9.4% 7.1% 13.6% Source: Company, BOBCAPS FY15 includes 15 months as the company changed its financial year-end from December to March. QoQ (%) Equity research 2

Financials Exhibit 3: Income Statement Net sales 20,652 26,940 23,726 26,574 30,560 growth (%) 12.1 6.5 7.9 12.0 15.0 COGS 3,346 4,284 3,991 4,390 4,859 Staff Cost 2,133 3,119 2,610 3,056 3,667 R&D Cost (1,186) (1,106) (1,186) (1,329) (1,528) SG&A Cost 13,139 17,294 15,517 17,220 19,405 EBITDA 3,220 3,349 2,795 3,237 4,156 growth (%) 17 (0) (17) 16 28 Depreciation 592 792 698 782 899 EBIT 2,627 2,557 2,097 2,455 3,257 Other income 315 432 437 458 481 Interest paid 13 18 100 107 97 Extraordinary/Exceptional items (101) 315 - - - PBT 2,829 3,287 2,434 2,807 3,642 Tax 920 975 799 921 1,195 Minority interest - - - - - PAT 1,909 2,312 1,636 1,886 2,447 Non-recurring items 101 (315) - - - Adjusted PAT 2,010 1,996 1,636 1,886 2,447 Exhibit 4: Balance Sheet Cash & Bank balances 2,558 2,101 1,882 1,798 1,708 Other Current assets 7,862 9,824 9,896 11,119 12,671 Investments - - - - - Net fixed assets 3,393 4,436 5,446 6,666 7,864 Intangible assets 8 9 16 19 20 Total assets 13,820 16,370 17,240 19,602 22,264 Current liabilities 3,738 4,418 4,171 4,971 5,620 Borrowings 793 978 1,017 1,078 1,079 Other non-current liabilities 891 762 645 768 991 Current/Non-current liabilities 5,421 6,158 5,832 6,816 7,689 Share capital 643 643 643 643 643 Reserves & surplus 7,756 9,569 10,765 12,143 13,932 Shareholders' funds 8,399 10,212 11,407 12,786 14,574 Total liabilities 13,820 16,370 17,240 19,602 22,264 Equity research 3

Exhibit 5: Cash Flow Statement Profit after tax 1,909 2,312 1,636 1,886 2,447 Depreciation 352 334 222 258 298 Chg in working capital (618) (1,411) (437) (300) (680) Total tax paid (237) - - - - Net Extra-ordinary income 101 (315) - - - Cash flow from operations 1,507 919 1,421 1,845 2,065 Capital expenditure (455) (1,181) (1,232) (1,479) (1,496) Change in investments - - - - - Acquisition of Goodwill (1) (2) (7) (3) (1) Cash flow from investments (457) (1,182) (1,239) (1,482) (1,497) Free cash flow 1,051 (263) 182 363 567 Issue of shares - - - - - Net inc/dec in debt 232 185 39 61 1 Dividend (incl. tax) (489) (489) (440) (508) (658) Other financing activities 225 (10) 0 0 (0) Net Extra-ordinary income (101) 315 - - - Cash flow from financing (32) (314) (401) (447) (657) Inc/(Dec) in Cash & Bank bal. 918 (262) (219) (84) (90) Exhibit 6: Ratio analysis Y/E Mar CY13 FY15(15M) FY16 FY17 FY18 Per share data (Rs) EPS 15.6 15.5 12.7 14.7 19.0 CEPS 40.5 43.4 36.3 41.5 52.1 DPS 7.6 9.7 6.8 7.9 10.2 BV 126.3 154.7 173.3 194.8 222.6 Profitability ratios (%) Gross margins 73.5 72.5 72.2 72.0 72.1 Operating margins 15.6 12.4 11.8 12.2 13.6 Net margins 9.7 7.4 6.9 7.1 8.0 Valuation ratios (x) PE 30.4 30.6 37.4 32.4 25.0 P/BV 3.7 3.1 2.7 2.4 2.1 EV/EBITDA 8.9 8.5 10.2 8.8 6.9 EV/Sales 1.4 1.1 1.2 1.1 0.9 RoE 27.1 22.1 15.5 15.9 18.2 RoCE 25.0 20.3 14.8 15.2 17.3 RoIC 34.2 26.3 17.1 17.1 19.2 Equity research 4

Sales and Dealing Team Purvesh Shelatkar Senior Vice President & Head Equity +91-22-6138 9330 purveshshelatkar@bobcaps.in Anil Pawar Senior Manager Dealing +91-22-6138 9325 anil@bobcaps.in Sachin Sambare Manager Dealing +91-22-61389331/33 sachin.sambare@bobcaps.in Ashwin Patil Executive Dealing +91-22-6138 9326 ashwin@bobcaps.in Research Team Sectors Vaishali Parkar Kumar Analyst Agri, Auto, Defence +91-22-6138 9382 vaishali.parkar@bobcaps.in Padmaja Ambekar Analyst Auto Ancillary, Infra, Midcap +91-22-6138 9381 padmaja.ambekar@bobcaps.in Akanksha Tripathi Analyst Footwear, FMCG +91-22-6138 9383 akanksha.tripathi@bobcaps.in Rishabh Mehta Associate +91-22-6138 9384 rishabh.mehta@bobcaps.in Hareesha Kakkera Associate +91-22-6138 9351 hareesha@bobcaps.in UTI Tower, 3rd Floor, South Wing, Bandra-Kurla Complex, Bandra (E), Mumbai - 400 051. India. Ph.: +91.22.6138.9300 Fax: +91.22.6671.8535 Email: research@bobcaps.in Web: www.bobcaps.in NSE SEBI No. (CASH): INB231304537 NSE SEBI No. (DERIVATIVES): INF231304537 BSE SEBI No. : INB011304533 Disclaimer BUY. We expect the stock to deliver >15% absolute returns. HOLD. We expect the stock to deliver 5-15% absolute returns. SELL. We expect the stock to deliver <5% absolute returns. Not Rated (NR). We have no investment opinion on the stock. The BoB Capital Markets research team hereby certifies that all of the views expressed in this report accurately reflect our personal views about the subject company or companies and its or their securities. We also certify that no part of our compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report." BOB Capital Markets Ltd. generally prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, BOB Capital Markets Ltd. generally prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover. Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. This material should not be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer or solicitation would be illegal. We are not soliciting any action based on this material. It is for the general information of clients of BOB Capital Markets Ltd. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this material, clients should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice. The price and value of the investments referred to in this material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. BOB Capital Markets Ltd. does not provide tax advice to its clients, and all investors are strongly advised to consult with their tax advisers regarding any potential investment in certain transactions including those involving futures, options, and other derivatives as well as non-investment-grade securities that give rise to substantial risk and are not suitable for all investors. The material is based on information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied on as such. Opinions expressed are our current opinions as of the date appearing on this material only. We endeavor to update on a reasonable basis the information discussed in this material, but regulatory, compliance, or other reasons may prevent us from doing so. We and our affiliates, officers, directors, and employees, including persons involved in the preparation or issuance of this material, may from time to time have "long" or "short" positions in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein and may from time to time add to or dispose of any such securities (or investment). We and our affiliates may act as market maker or assume an underwriting commitment in the securities of companies discussed in this document (or in related investments), may sell them to or buy them from customers on a principal basis and may also perform or seek to perform investment banking or advisory services for or relating to those companies and may also be represented in the supervisory board or any other committee of those companies. For the purpose of calculating whether BOB Capital Markets Ltd. and its affiliates hold, beneficially own, or control, including the right to vote for directors, 1% or more of the equity shares of the subject, the holding of the issuer of a research report is also included. BOB Capital Markets Ltd. and its non-us affiliates may, to the extent permissible under applicable laws, have acted on or used this research to the extent that it relates to non-us issuers, prior to or immediately following its publication. Foreign currency denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. In addition, investors in securities such as ADRs, the value of which are influenced by foreign currencies, affectively assume currency risk. In addition, options involve risks and are not suitable for all investors. Please ensure that you have read and understood the current derivatives risk disclosure document before entering into any derivative transactions. In the US, this material is only for Qualified Institutional Buyers as defined under rule 144(a) of the Securities Act, 1933.No part of this material may be (i) copied, photocopied, or duplicated in any form by any means or (ii) redistributed without BOB Capital Markets Ltd. s prior written consent. No part of this document may be distributed in Canada or used by private customers in the United Kingdom. Equity research 5